Provexis plc (AIM:PXS)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 14.66M |
| Revenue (ttm) | 1.29M |
| Net Income (ttm) | -452.72K |
| Shares Out | 2.35B |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,445 |
| Average Volume | 1,371,910 |
| Open | 0.589 |
| Previous Close | 0.625 |
| Day's Range | 0.589 - 0.589 |
| 52-Week Range | 0.400 - 0.950 |
| Beta | 0.25 |
| RSI | 53.65 |
| Earnings Date | Dec 31, 2025 |
About Provexis
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product. The company sells its products through company’s website a... [Read more]
Financial Performance
In 2024, Provexis's revenue was 1.29 million, an increase of 61.13% compared to the previous year's 801,964. Losses were -452,720, -22.78% less than in 2023.
Financial StatementsNews
AIM Market Roundup: Provexis, Geo Exploration, Sabien
Provexis, Geo Exploration, Sabien are today's top risers, while Bigblu Broadband, Empyrean Energy take the biggest fall on London's AIM